Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NATALIZUMAB Cause Poor venous access? 422 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 422 reports of Poor venous access have been filed in association with NATALIZUMAB (TYRUKO). This represents 0.7% of all adverse event reports for NATALIZUMAB.

422
Reports of Poor venous access with NATALIZUMAB
0.7%
of all NATALIZUMAB reports
3
Deaths
52
Hospitalizations

How Dangerous Is Poor venous access From NATALIZUMAB?

Of the 422 reports, 3 (0.7%) resulted in death, 52 (12.3%) required hospitalization, and 1 (0.2%) were considered life-threatening.

Is Poor venous access Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 422 reports have been filed with the FAERS database.

What Other Side Effects Does NATALIZUMAB Cause?

Multiple sclerosis relapse (6,478) Fatigue (4,456) Multiple sclerosis (4,078) Memory impairment (3,024) Malaise (2,523) Fall (2,481) Headache (2,476) Gait disturbance (2,427) Prescribed underdose (2,162) Maternal exposure during pregnancy (1,948)

What Other Drugs Cause Poor venous access?

VEDOLIZUMAB (1,043) INFLIXIMAB (917) INFLIXIMAB-DYYB (782) ECULIZUMAB (555) HUMAN IMMUNOGLOBULIN G (504) RITUXIMAB (299) TOCILIZUMAB (287) METHOTREXATE (257) ABATACEPT (249) IDURSULFASE (175)

Which NATALIZUMAB Alternatives Have Lower Poor venous access Risk?

NATALIZUMAB vs NATALIZUMAB-SZTN NATALIZUMAB vs NATAMYCIN NATALIZUMAB vs NATEGLINIDE NATALIZUMAB vs NAVITOCLAX NATALIZUMAB vs NAXITAMAB-GQGK

Related Pages

NATALIZUMAB Full Profile All Poor venous access Reports All Drugs Causing Poor venous access NATALIZUMAB Demographics